
GLP-1 Drugs and Muscle Loss: What Lifters Should Know
GLP-1 drugs cause some lean loss, about 26% to 40% of weight lost in trials. Protein targets, lifting data from T-REx, WADA rules and muscle-sparing drugs.
Written by Dr. Andrii Kaleniuk. Updated November 15, 2026.
Yes, GLP-1 drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) cause some loss of lean mass along with fat, but in the main trials the share was about one quarter to two fifths of the weight lost, and strength training appears to reduce it. In the SURMOUNT-1 body-scan substudy, about 26% of the weight lost on tirzepatide was lean mass, almost the same as the 25% lost by people dieting on placebo. "Lean mass" on these scans is not the same as muscle: it also includes water, organs and connective tissue, and one MRI study found muscle quality improved as fat inside the muscle fell. A 2025 joint advisory from four nutrition and obesity societies recommends strength training at least three times a week and higher protein intake. The catch for lifters is that no controlled trial has studied trained lifters or athletes on these drugs. This guide covers the trial numbers, protein targets, the new T-REx training study, anti-doping rules and the experimental muscle-sparing drugs in development.
GLP-1 Drugs and Muscle Loss: The Short Answer
- 1Lean mass made up roughly 26% (tirzepatide) to about 40% (semaglutide) of weight lost in the main body-scan studies.
- 2That share was similar to dieting alone in SURMOUNT-1 (25% on placebo).
- 3DXA "lean mass" includes water and organs, so actual muscle loss is likely smaller; one advisory estimates about 20% of weight lost.
- 4A joint advisory recommends strength training 3 or more times a week and 1.2 to 1.6 g of protein per kg (or 80 to 120 g a day).
- 5In the T-REx study, people who lifted lost 25% less lean tissue and gained strength, according to a university press release.
- 6No trials exist in trained lifters; semaglutide and tirzepatide are monitored but not banned by WADA.
How Much Muscle Do People Lose on GLP-1 Drugs?
The best data come from DXA scans, a low-dose X-ray that splits the body into fat, bone and "lean" tissue. In a SURMOUNT-1 substudy of 160 adults published by Look and colleagues in 2025, people on tirzepatide lost 21.3% of their body weight over 72 weeks, against 5.3% on placebo. Their fat mass fell by 33.9% and lean mass by 10.9%, so lean mass was about 26% of the weight they lost. In the STEP 1 DXA substudy of 140 adults presented in 2021, semaglutide reduced total fat mass by 19.3%, visceral (belly organ) fat by 27.4% and lean mass by 9.7% over 68 weeks; the proportion of the body made up of lean mass actually rose by about 3 percentage points. A 2025 joint nutrition advisory restates STEP 1 as an average loss of 13.6 kg, of which 8.3 kg (62%) was fat and 5.3 kg (38%) lean. Claims of "20 to 40%" lean loss that circulate online roughly match these figures, but we could not trace that range to a single primary study.
Lean mass in key GLP-1 body-composition studies
STEP 1 substudy (n=140)
Semaglutide
DXA, 68 weeks
-13.6 kg average
-19.3%
-9.7%
About 38% to 40%
SURMOUNT-1 substudy (n=160)
Tirzepatide vs placebo
DXA, 72 weeks
-21.3% vs -5.3%
-33.9% vs -8.2%
-10.9% vs -2.6%
About 26% vs 25%
BELIEVE, phase 2 (n=507)
Bimagrumab + semaglutide vs semaglutide
72 weeks
-22.1% vs -15.7%
Fat 92% vs 76% of loss
-2.9% vs -7.4%
About 8% vs 24%
QUALITY, phase 2b (n=168, age 60+)
Enobosarm + semaglutide vs placebo + semaglutide
16 weeks
Not stated in company release
Not stated
Lean mass preserved with enobosarm
34% in placebo arm
T-REx (n=120, age 50 to 70)
Tirzepatide with or without lifting
40 weeks
About -22.3 kg vs -22.6 kg
Not stated in release
25% less lean loss with lifting
Not stated in release
Is the Lean Mass Lost on Semaglutide and Tirzepatide Actually Muscle?
Only partly. DXA counts everything that is not fat or bone as lean mass, including water, organs such as the liver, and connective tissue. When people lose a lot of weight, some of that lean loss is water and smaller organs rather than skeletal muscle. The joint advisory estimates that actual muscle loss is about 20% of weight lost, and its modelling suggests muscle makes up roughly 10 to 15% of weight lost in women and 20 to 25% in men who do not strength train. The SURMOUNT-1 authors also noted that DXA cannot assess muscle quality. For a lifter, the scan number is a rough guide, not a direct measure of how much contractile muscle you have lost.
Is GLP-1 Lean Loss Worse Than Dieting Alone?
The best comparison so far suggests not. In SURMOUNT-1, lean mass made up about 26% of weight lost on tirzepatide and about 25% on placebo, where people were following a reduced-calorie diet and activity advice. The drug group lost much more weight in total, so they lost more lean mass in kilograms, but the proportion was similar. In other words, the lean loss seems to come mainly from the size of the weight loss, not from a special effect of the drug on muscle. That is the same trade-off any hard cut involves, as discussed in tirzepatide for cutting.
Does Muscle Quality Improve Even as Size Drops?
One study suggests it may. In an MRI substudy of the SURPASS-3 trial in 246 people with type 2 diabetes, published by Sattar and colleagues in Lancet Diabetes & Endocrinology in April 2025, muscle volume on tirzepatide fell in line with what would be predicted for the amount of weight lost, based on UK Biobank data. Fat stored inside the muscle, which is linked to poorer muscle function, fell more than predicted. According to a published synopsis, the authors described the loss of muscle volume as an adaptive response to carrying less weight. This was not a study of lifters, and MRI volume does not measure strength directly.
How Much Protein Do GLP-1 Users Need?
The 2025 joint advisory, "Nutritional priorities to support GLP-1 therapy for obesity" from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society, starts from the standard recommended intake of 0.8 g of protein per kg of body weight a day. It notes that "higher targets, such as 1.2–1.6 g/kg/d, have also been proposed," suggests 1.5 g per kg of fat-free mass as a more accurate target, and offers an absolute range of 80 to 120 g a day. It advises against prolonged intakes of 2 g per kg or more and notes that using total body weight may overestimate needs in people with obesity. Many lifters already eat at or above these levels; the practical challenge on a GLP-1 is reaching them when appetite is low.
2025 joint advisory targets for people on GLP-1 therapy
Protein, minimum
0.8 g per kg per day
Standard recommended dietary allowance
Protein, higher target
1.2 to 1.6 g per kg per day
"Proposed" higher range
Protein, fat-free mass basis
1.5 g per kg of fat-free mass
Suggested as more accurate
Protein, absolute
80 to 120 g per day
Practical daily range
Protein, upper limit
Avoid prolonged 2 g per kg per day or more
Body weight may overestimate needs
Strength training
At least 3 times a week
Regular resistance exercise
Aerobic exercise
At least 150 minutes a week
Moderate intensity
Does Lifting Prevent Muscle Loss on Tirzepatide?
It appears to help a lot, according to early results. A University of Western Australia news release dated November 10, 2026 describes the T-REx study by Green and colleagues, reported as published in Nature Medicine. It followed 120 adults aged 50 to 70 on tirzepatide for 40 weeks; half did resistance training three times a week. According to the release, both groups lost similar weight, about 22.3 kg and 22.6 kg, but the training group lost 25% less lean tissue, and their strength rose by about 10% while it fell by about 10% in the group that did not train. The release says the manufacturer supplied the drug. We could not confirm from the release whether participants were randomly assigned or read the full methods, so these figures should be treated as preliminary until the paper is examined. Another trial testing resistance exercise plus protein during semaglutide or tirzepatide treatment is registered as NCT06885736.
Are There Studies in Athletes or Experienced Lifters?
No. We found no controlled trial of GLP-1 drugs in trained lifters, bodybuilders or competitive athletes. All the data above come from people with obesity or type 2 diabetes, most of them untrained, who start with more fat and respond differently to training. What we know about lifters comes from informal reports: a 2025 study by Lazuras and colleagues analysed about 12,400 bodybuilding forum posts describing GLP-1 use, including cycling these drugs and stacking them with anabolic steroids. That tells us the practice exists, not whether it is safe or effective. Lifters also discuss newer drugs such as retatrutide, which is not approved; see retatrutide for bodybuilding and tirzepatide vs retatrutide for getting shredded. Products sold as "research use only" are unapproved and of uncertain content, as explained in research use only peptides.
Are GLP-1 Drugs Banned in Sport?
Not as of November 2026. According to a summary of World Anti-Doping Agency (WADA) rules, semaglutide has been on WADA's monitoring program since 2024 and tirzepatide was added on January 1, 2026. Monitoring means WADA tracks use to look for patterns of misuse; neither drug is on the prohibited list. That could change, so tested athletes should check the current list and their federation's rules each year. Our overview of peptides banned by WADA covers related compounds.
What Are Bimagrumab and Enobosarm, and When Could They Arrive?
Both are experimental drugs being tested to protect muscle during GLP-1 weight loss. Neither is approved, and doses are not discussed here.
Bimagrumab is an antibody that blocks signals that limit muscle growth. In Lilly's phase 2 BELIEVE trial of 507 adults over 72 weeks, published by Heymsfield and colleagues in Nature Medicine in March 2026, bimagrumab plus semaglutide produced 22.1% weight loss against 15.7% with semaglutide alone. Fat made up 92% of the weight lost with the combination against 76% with semaglutide alone, and lean mass fell 2.9% against 7.4%; bimagrumab alone increased lean mass by 2.5%. Side effects with bimagrumab included muscle spasms, diarrhea and acne. A phase 2 trial of bimagrumab with tirzepatide (NCT06643728, about 240 people) had a primary completion date of March 31, 2026, but we found no results.
Enobosarm is a selective androgen receptor modulator, a drug designed to act on muscle and bone like testosterone with fewer effects elsewhere. In Veru's phase 2b QUALITY trial of 168 adults aged 60 or older over 16 weeks with semaglutide, enobosarm preserved lean mass, while the placebo group lost 34% of its weight as lean mass, and it gave a 59.8% relative reduction in the share of people whose stair-climbing ability fell by 10% or more. Veru says the FDA outlined two possible phase 3 paths in September 2025. Its PLATEAU trial in about 200 adults aged 65 or older with a BMI of 35 or more on Wegovy enrolled its first patient on March 9, 2026, with interim results expected in the first quarter of 2027 and topline results in the fourth quarter of 2027. Both drugs are years from possible approval; how unapproved compounds are regulated is covered in FDA peptide rules for 2026.
How Should Lifters Track Muscle on a GLP-1?
- 1Keep a training log: holding or increasing your lifts is the most practical sign you are keeping muscle.
- 2Use the same scale at the same time of day, and track waist measurements alongside weight.
- 3If you use DXA, scan on the same machine under similar conditions, and remember that water and glycogen shifts change "lean" readings.
- 4Track daily protein against a target your clinician agrees with, especially on low-appetite days.
- 5Watch for strength falling week after week, which may mean the deficit is too steep.
When to Talk to Your Doctor
- 1Before starting any GLP-1 drug, and only with a prescription for an approved product
- 2If your strength keeps falling despite training and adequate protein
- 3If you cannot eat enough protein because of nausea or low appetite
- 4If you are a tested athlete and are prescribed a GLP-1 for a medical reason
- 5If you have kidney disease, before raising protein intake
- 6If you are considering unapproved or "research" products, including retatrutide
What to Do Next: Questions to Ask Your Doctor
- 1What protein target is right for me, based on my weight, kidney function and training?
- 2How fast should I be losing weight to protect muscle?
- 3Would a DXA scan before and during treatment be useful for me?
- 4Should my dose increases be slowed if my training performance drops?
- 5Can I be referred to a dietitian or exercise professional?
- 6Is a clinical trial of a muscle-sparing combination suitable for me?
The Bottom Line
GLP-1 drugs do cause some lean mass loss, but in the main trials the proportion was similar to dieting alone, and DXA overstates how much of it is muscle. Muscle quality may even improve. The 2025 joint advisory's targets of strength training at least three times a week and 1.2 to 1.6 g of protein per kg are a sensible baseline, and early T-REx results suggest lifting cuts lean loss and preserves strength. What lifters still lack is any controlled data in trained people, so treat claims about getting shredded on a GLP-1 without losing muscle with caution.
FAQ
Some lean mass is lost with semaglutide, about 38% to 40% of weight lost in the STEP 1 scan study, but DXA lean mass includes water and organs, so actual muscle loss is likely smaller.
A 2025 joint advisory suggests 1.2 to 1.6 g per kg of body weight a day, or 80 to 120 g a day, and avoiding prolonged intakes of 2 g per kg or more. Ask your clinician for a personal target.
Building muscle in a large calorie deficit is hard. In the T-REx study, people on tirzepatide who lifted three times a week gained about 10% in strength and lost less lean tissue, according to a press release.
No. Tirzepatide was added to WADA's monitoring program on January 1, 2026, and semaglutide has been monitored since 2024, but neither is prohibited as of November 2026.
In the BELIEVE phase 2 trial, the combination produced 22.1% weight loss against 15.7% with semaglutide alone, with lean mass falling 2.9% against 7.4%. Bimagrumab is not approved.
The evidence supports strength training at least three times a week, adequate protein and a moderate rate of weight loss. Track your lifts and discuss your plan with your prescriber.
Sources
- 1Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight, Diabetes, Obesity and Metabolism, 2025
- 2Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, American Journal of Clinical Nutrition, 2025
- 3Resistance training key to maintaining muscle function during GLP-1 weight loss, University of Western Australia news release, 2026 (T-REx)
- 4Halsey G. Semaglutide 2.4 mg Reduces Visceral Adiposity, Improves Lean Body Mass-to-Fat Mass Ratio, Patient Care, 2021
- 5How does muscle composition change after weight loss from tirzepatide in patients with diabetes?, Epocrates, 2025 (SURPASS-3 MRI)
- 6Halpern L. Bimagrumab-Semaglutide Combination Achieves Significant Weight Loss While Preserving Muscle Mass, Pharmacy Times, 2026 (BELIEVE)
- 7LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy (NCT06885736), ClinicalTrials.gov
- 8Eli Lilly. Phase 2 study of bimagrumab and tirzepatide (NCT06643728), trial registry listing
- 9Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress, Veru Inc., 2025
- 10Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss, Veru Inc., March 2026
This article summarizes published research for general information and is not medical advice. Bimagrumab, enobosarm and retatrutide are investigational and not approved. Several studies cited were funded by drug manufacturers, and the T-REx drug was supplied by its manufacturer.

Dr. Andrii Kaleniuk
Author
Comments (0)
Be the first to comment on this article.




